Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
CENTOCOR, INC.
🇺🇸
United States
Country
🇺🇸
United States
Ownership
Subsidiary
Employees
1.2K
Market Cap
-
Website
http://www.centocor.com
Clinical Trials
Related News
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Phase 1
Completed
Conditions
Prostatic Neoplasms
Interventions
Drug: CNTO 328
Drug: Docetaxel
Subscribe
First Posted Date
2006-11-22
Last Posted Date
2014-05-26
Lead Sponsor
Centocor, Inc.
Target Recruit Count
40
Registration Number
NCT00401765
Subscribe
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Phase 2
Terminated
Conditions
Cancer, Prostate
Interventions
Drug: Mitoxantrone
Drug: Siltuximab
Drug: Prednisone
Subscribe
First Posted Date
2006-10-11
Last Posted Date
2014-08-20
Lead Sponsor
Centocor, Inc.
Target Recruit Count
106
Registration Number
NCT00385827
Subscribe
A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Completed
Conditions
COPD
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Collection of safety data for Cohort 1
Subscribe
First Posted Date
2006-09-26
Last Posted Date
2013-09-04
Lead Sponsor
Centocor, Inc.
Target Recruit Count
88
Registration Number
NCT00380796
Subscribe
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Golimumab
Drug: Placebo
Drug: Methotrexate
Subscribe
First Posted Date
2006-08-08
Last Posted Date
2014-07-29
Lead Sponsor
Centocor, Inc.
Target Recruit Count
643
Registration Number
NCT00361335
Subscribe
A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
Phase 3
Completed
Conditions
Ulcerative Colitis
Interventions
Biological: infliximab
Subscribe
First Posted Date
2006-06-13
Last Posted Date
2013-07-30
Lead Sponsor
Centocor, Inc.
Target Recruit Count
60
Registration Number
NCT00336492
Subscribe
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: Placebo
Drug: Ustekinumab
Subscribe
First Posted Date
2006-05-03
Last Posted Date
2015-04-20
Lead Sponsor
Centocor, Inc.
Target Recruit Count
320
Registration Number
NCT00320216
Subscribe
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
Phase 3
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: Placebo
Biological: Golimumab 100 mg
Biological: Golimumab 50 mg
Subscribe
First Posted Date
2006-03-07
Last Posted Date
2014-02-27
Lead Sponsor
Centocor, Inc.
Target Recruit Count
461
Registration Number
NCT00299546
Subscribe
A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab
Phase 3
Completed
Conditions
Angioplasty, Transluminal, Percutaneous Coronary
Interventions
Other: Angioplasty
Other: Intracoronary Stent
Drug: Abxicimab
Drug: Heparin
Drug: Placebo
Subscribe
First Posted Date
2006-01-02
Last Posted Date
2015-05-25
Lead Sponsor
Centocor, Inc.
Target Recruit Count
2399
Registration Number
NCT00271401
Subscribe
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
Phase 3
Completed
Conditions
Angioplasty, Transluminal, Percutaneous Coronary
Interventions
Drug: Heparin
Drug: Placebo
Drug: Abciximab
Subscribe
First Posted Date
2005-12-26
Last Posted Date
2015-05-25
Lead Sponsor
Centocor, Inc.
Target Recruit Count
2792
Registration Number
NCT00269880
Subscribe
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
Phase 3
Completed
Conditions
Crohn Disease
Interventions
Drug: Infliximab 10 mg/kg
Drug: Placebo
Drug: Infliximab 5 mg/kg
Subscribe
First Posted Date
2005-12-26
Last Posted Date
2014-11-04
Lead Sponsor
Centocor, Inc.
Target Recruit Count
94
Registration Number
NCT00269841
Subscribe
Prev
1
2
3
4
5
6
8
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy